Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence
Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic p...
Gespeichert in:
Veröffentlicht in: | Gynecologic oncology 2009-02, Vol.112 (2), p.342-347 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 347 |
---|---|
container_issue | 2 |
container_start_page | 342 |
container_title | Gynecologic oncology |
container_volume | 112 |
creator | Fujimoto, Toshio Nanjyo, Hiroshi Fukuda, Jun Nakamura, Akira Mizunuma, Hideki Yaegashi, Nobuo Sugiyama, Toru Kurachi, Hirohisa Sato, Akira Tanaka, Toshinobu |
description | Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients. |
doi_str_mv | 10.1016/j.ygyno.2008.10.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66830909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825808008913</els_id><sourcerecordid>66830909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</originalsourceid><addsrcrecordid>eNqFkUGLFDEQhYMo7rj6CwTJyVuPlaSTTgsKy7K6Cwsedj15CJmkes1sT2dM0sL8e9POgOBlTwWP915RXxHylsGaAVMftuvDw2GKaw6gq7IG1j8jKwa9bJSW_XOyAuih0VzqM_Iq5y0ACGD8JTljPSgOmq_Ij6vJxx2WFGLwdC6YwoTU2clh-kivQy5xb8vPOMaH4OxIU8iPdLCuxJRpHOgYF9VOnvrqtVOhCd2cEtaC1-TFYMeMb07znHz_cnV_ed3cfvt6c3lx27i206XhyiuutBPSd952IDV02EkuXC_bTSdAWtV6QOe6oVdeetRWIiBvN63lHRPn5P2xd5_irxlzMbuQHY6jnTDO2SilRSXRV6M4Gl2KOScczD6FnU0Hw8AsTM3W_GVqFqaLWJnW1LtT_bzZof-XOUGshk9HA9YjfwdMJruwAPChwijGx_DEgs__5d0YpgX3Ix4wb-OcpsrPMJO5AXO3vHX5Kuha0jMh_gD6P57-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66830909</pqid></control><display><type>article</type><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</creator><creatorcontrib>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</creatorcontrib><description>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2008.10.019</identifier><identifier>PMID: 19062082</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant chemotherapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Architectural grade ; Carcinoma, Endometrioid - drug therapy ; Carcinoma, Endometrioid - pathology ; Carcinoma, Endometrioid - surgery ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Distant recurrence ; Endometrioid uterine cancer ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Local recurrence ; Lymph Node Excision ; Lymphatic Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics and Gynecology ; Pelvic lymph node metastasis ; Risk Factors ; Uterine Neoplasms - drug therapy ; Uterine Neoplasms - pathology ; Uterine Neoplasms - surgery</subject><ispartof>Gynecologic oncology, 2009-02, Vol.112 (2), p.342-347</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</citedby><cites>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825808008913$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19062082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujimoto, Toshio</creatorcontrib><creatorcontrib>Nanjyo, Hiroshi</creatorcontrib><creatorcontrib>Fukuda, Jun</creatorcontrib><creatorcontrib>Nakamura, Akira</creatorcontrib><creatorcontrib>Mizunuma, Hideki</creatorcontrib><creatorcontrib>Yaegashi, Nobuo</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Kurachi, Hirohisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Tanaka, Toshinobu</creatorcontrib><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Architectural grade</subject><subject>Carcinoma, Endometrioid - drug therapy</subject><subject>Carcinoma, Endometrioid - pathology</subject><subject>Carcinoma, Endometrioid - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Distant recurrence</subject><subject>Endometrioid uterine cancer</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Local recurrence</subject><subject>Lymph Node Excision</subject><subject>Lymphatic Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Pelvic lymph node metastasis</subject><subject>Risk Factors</subject><subject>Uterine Neoplasms - drug therapy</subject><subject>Uterine Neoplasms - pathology</subject><subject>Uterine Neoplasms - surgery</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGLFDEQhYMo7rj6CwTJyVuPlaSTTgsKy7K6Cwsedj15CJmkes1sT2dM0sL8e9POgOBlTwWP915RXxHylsGaAVMftuvDw2GKaw6gq7IG1j8jKwa9bJSW_XOyAuih0VzqM_Iq5y0ACGD8JTljPSgOmq_Ij6vJxx2WFGLwdC6YwoTU2clh-kivQy5xb8vPOMaH4OxIU8iPdLCuxJRpHOgYF9VOnvrqtVOhCd2cEtaC1-TFYMeMb07znHz_cnV_ed3cfvt6c3lx27i206XhyiuutBPSd952IDV02EkuXC_bTSdAWtV6QOe6oVdeetRWIiBvN63lHRPn5P2xd5_irxlzMbuQHY6jnTDO2SilRSXRV6M4Gl2KOScczD6FnU0Hw8AsTM3W_GVqFqaLWJnW1LtT_bzZof-XOUGshk9HA9YjfwdMJruwAPChwijGx_DEgs__5d0YpgX3Ix4wb-OcpsrPMJO5AXO3vHX5Kuha0jMh_gD6P57-</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Fujimoto, Toshio</creator><creator>Nanjyo, Hiroshi</creator><creator>Fukuda, Jun</creator><creator>Nakamura, Akira</creator><creator>Mizunuma, Hideki</creator><creator>Yaegashi, Nobuo</creator><creator>Sugiyama, Toru</creator><creator>Kurachi, Hirohisa</creator><creator>Sato, Akira</creator><creator>Tanaka, Toshinobu</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><author>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Architectural grade</topic><topic>Carcinoma, Endometrioid - drug therapy</topic><topic>Carcinoma, Endometrioid - pathology</topic><topic>Carcinoma, Endometrioid - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Distant recurrence</topic><topic>Endometrioid uterine cancer</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Local recurrence</topic><topic>Lymph Node Excision</topic><topic>Lymphatic Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Pelvic lymph node metastasis</topic><topic>Risk Factors</topic><topic>Uterine Neoplasms - drug therapy</topic><topic>Uterine Neoplasms - pathology</topic><topic>Uterine Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujimoto, Toshio</creatorcontrib><creatorcontrib>Nanjyo, Hiroshi</creatorcontrib><creatorcontrib>Fukuda, Jun</creatorcontrib><creatorcontrib>Nakamura, Akira</creatorcontrib><creatorcontrib>Mizunuma, Hideki</creatorcontrib><creatorcontrib>Yaegashi, Nobuo</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Kurachi, Hirohisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Tanaka, Toshinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujimoto, Toshio</au><au>Nanjyo, Hiroshi</au><au>Fukuda, Jun</au><au>Nakamura, Akira</au><au>Mizunuma, Hideki</au><au>Yaegashi, Nobuo</au><au>Sugiyama, Toru</au><au>Kurachi, Hirohisa</au><au>Sato, Akira</au><au>Tanaka, Toshinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>112</volume><issue>2</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19062082</pmid><doi>10.1016/j.ygyno.2008.10.019</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-8258 |
ispartof | Gynecologic oncology, 2009-02, Vol.112 (2), p.342-347 |
issn | 0090-8258 1095-6859 |
language | eng |
recordid | cdi_proquest_miscellaneous_66830909 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adjuvant chemotherapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Architectural grade Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - pathology Carcinoma, Endometrioid - surgery Chemotherapy, Adjuvant Disease-Free Survival Distant recurrence Endometrioid uterine cancer Female Hematology, Oncology and Palliative Medicine Humans Local recurrence Lymph Node Excision Lymphatic Metastasis Middle Aged Multivariate Analysis Neoplasm Metastasis Neoplasm Recurrence, Local - pathology Neoplasm Staging Obstetrics and Gynecology Pelvic lymph node metastasis Risk Factors Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology Uterine Neoplasms - surgery |
title | Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endometrioid%20uterine%20cancer:%20Histopathological%20risk%20factors%20of%20local%20and%20distant%20recurrence&rft.jtitle=Gynecologic%20oncology&rft.au=Fujimoto,%20Toshio&rft.date=2009-02-01&rft.volume=112&rft.issue=2&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2008.10.019&rft_dat=%3Cproquest_cross%3E66830909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66830909&rft_id=info:pmid/19062082&rft_els_id=1_s2_0_S0090825808008913&rfr_iscdi=true |